New research published in Frontiers in Pharmacology explores the cost-utility of adding ezetimibe to moderate-intensity statin therapy for secondary prevention in patients with Acute Coronary Syndrome (ACS) who are intolerant to high-intensity statins. The study, conducted by researchers in Thailand, suggests that this treatment approach may be a cost-effective strategy for improving Acute Coronary Syndrome management in this specific patient population.
Acute Coronary Syndrome, a serious cardiovascular condition, often necessitates high-intensity statin therapy for secondary prevention to reduce the risk of further cardiac events. However, a notable subset of patients experiences adverse effects, such as statin-associated muscle symptoms, limiting their ability to tolerate these higher doses. For these individuals, clinical guidelines recommend exploring alternative lipid-lowering strategies.
Understanding Acute Coronary Syndrome Management Challenges
The Heart Association of Thailand (2020) highlights the increasing burden of Acute Coronary Syndrome in the country, with significant hospitalisation and mortality rates. Elevated low-density lipoprotein cholesterol (LDL-C) is a primary modifiable risk factor for cardiovascular disease, making its reduction a key therapeutic target. While high-intensity statins are generally recommended, real-world data from studies like the Dyslipidemia International Study (DYSIS) II indicate that these regimens are often underutilised in Thai practice, with many patients receiving moderate-intensity statins.
Patient intolerance and adverse effects are significant contributors to this gap. Research in Thailand suggests that approximately 10% of individuals on high-intensity statins may discontinue therapy or show poor adherence due to muscle-related symptoms and potential drug interactions, according to studies by Supsongserm et al. (2013) and Boonmuang et al. (2013). For these patients, achieving LDL-C targets through other means becomes crucial, as underscored by findings from the LODESTAR trial (Hong et al., 2023), which indicated that a treat-to-target strategy was non-inferior to high-intensity statin therapy in preventing major cardiovascular events.
Evaluating Ezetimibe as an Add-on Therapy
Study Design and Methodology
The recent cost-utility analysis, led by Nattiwat Promchit and colleagues from Chiang Mai University, utilised a Markov model with four health states: no further event, non-fatal myocardial infarction (MI), non-fatal stroke, and death. The model compared two strategies: ezetimibe 10 mg daily added to moderate-intensity statin therapy (represented by simvastatin 40 mg) versus moderate-intensity statin therapy alone. Transition probabilities, utility values, and cost inputs were derived from the IMPROVE-IT trial and relevant literature, supplemented with Thailand-specific data. The intervention was considered cost-effective if the incremental cost-effectiveness ratio (ICER) fell below Thailand’s willingness-to-pay (WTP) threshold of 160,000 THB per Quality-Adjusted Life Year (QALY).
Key Findings on Cost-Effectiveness
The study’s findings suggest potential benefits for patients requiring careful Acute Coronary Syndrome management:
- From a societal perspective, adding ezetimibe yielded an ICER of 155,312 THB/QALY (approximately 4,400.4 USD/QALY).
- From the healthcare provider perspective, the ICER was 148,934 THB/QALY (approximately 4,219.7 USD/QALY).
- Both ICERs were below the 160,000 THB/QALY threshold, indicating potential cost-effectiveness.
- One-way sensitivity analysis identified the relative risk of death from myocardial infarction associated with ezetimibe as the most influential parameter.
- Probabilistic sensitivity analysis indicated a 56.8% probability of cost-effectiveness at the predefined threshold.
Implications for Clinical Practice
These results suggest that adding ezetimibe to moderate-intensity statin therapy may be a cost-effective option for secondary prevention of ACS in patients in Thailand who cannot tolerate high-intensity statins. This aligns with existing guidelines that recommend non-statin lipid-modifying agents for patients unable to achieve LDL-C targets with statins alone, as noted by Mach et al. (2020).
However, the authors advise appropriate caution in interpreting these findings. The base-case ICER was only marginally below the national threshold, and the probabilistic sensitivity analysis showed a 56.8% probability of cost-effectiveness, which indicates some uncertainty. Further real-world evidence and local economic evaluations could provide additional clarity on the long-term benefits and cost-effectiveness of this approach in diverse clinical settings.
Disclaimer: This article is for informational purposes only and does not constitute medical advice. Hemp Gazette does not provide medical recommendations, diagnoses, or treatment plans. Always consult a qualified healthcare practitioner before making any decisions regarding your health or any medical condition. Statements concerning the therapeutic uses of hemp, cannabis, or cannabinoid-derived products have not been evaluated by Australia’s Therapeutic Goods Administration (TGA). Medicinal cannabis products in Australia are accessed via prescription pathways under TGA regulation.
